This was also a factor when using the IGF2BP1 inhibitor BTYNB, for which 10 μM was sufficient to reduce cell proliferation in low- and intermediate-risk neuroblastoma cell lines [SK-N-AS and SK-N-BE(2)], and 15 μM was needed in the high-risk neuroblastoma cell line (SK-N-DZ), were reduced to 5 and 10 μM, respectively. Here, IGF2BP1 is linked to neuroblastoma.